Peter Atadja

Peter Atadja serves as the Chief Scientific Officer at Landcent Europe from June 2023 to December 2023, focusing on advancing research and development to achieve significant scientific and technological milestones. Prior to this role, Atadja was the Chief Scientific Advisor at Novartis, where responsibilities included co-leading the establishment of the scientific and operational strategy for the third global R&D center in Shanghai, China, as Executive Director/Head of Drug Discovery at Novartis Institutes for BioMedical Research (NIBR). Additionally, Atadja established the Epigenetics Drug Discovery program at Novartis, identifying and validating novel therapeutic targets for cancer. Educational qualifications include a PhD in Molecular Oncology from the University of Calgary and an MS in Medicinal and Pharmaceutical Chemistry from The Hebrew University of Jerusalem.